PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical

Published on: November 6, 2025

PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated.

For more details, please click here (Japanese language PDF).